• +1-646-491-9876
    • +91-20-67278686

    Search

    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016

    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016

    • Report Code ID: RW0001492663
    • Category Pharmaceuticals
    • No. of Pages 186
    • Publication Month Oct-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's, 'Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted pipeline therapeutics.

    The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Report Scope

    - The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
    - The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents 2
    List of Tables 4
    List of Figures 7
    Introduction 8
    Global Markets Direct Report Coverage 8
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Overview 9
    Therapeutics Development 10
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Stage of Development 10
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Therapy Area 11
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Indication 12
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Products Glance 15
    Late Stage Products 15
    Early Stage Products 16
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Companies 17
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Universities/Institutes 30
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Therapeutics Assessment 32
    Assessment by Monotherapy/Combination Products 32
    Assessment by Mechanism of Action 33
    Assessment by Route of Administration 34
    Assessment by Molecule Type 36
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Companies Involved in Therapeutics Development 38
    Abeome Corporation 38
    Alnylam Pharmaceuticals, Inc. 39
    AlphaMab Co., Ltd 40
    AstraZeneca Plc 41
    Aurigene Discovery Technologies Limited 42
    Avacta Group Plc 43
    BeiGene, Ltd. 44
    Bristol-Myers Squibb Company 45
    CBT Pharmaceuticals Inc 46
    CytomX Therapeutics, Inc. 47
    Eli Lilly and Company 48
    F. Hoffmann-La Roche Ltd. 49
    Genosco 51
    ImmunoCellular Therapeutics, Ltd. 52
    Immunocore Limited 53
    IO Biotech ApS 54
    Kadmon Corporation, LLC 55
    Kymab Limited 56
    MedImmune, LLC 57
    Merck KGaA 59
    Merus NV 60
    Novartis AG 61
    PsiOxus Therapeutics Limited 62
    Regeneron Pharmaceuticals Inc 63
    Shanghai Henlius Biotech Co., Ltd. 64
    Sorrento Therapeutics, Inc. 65
    Sutro Biopharma, Inc. 66
    Theravectys SA 67
    Tikcro Technologies, Ltd. 68
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drug Profiles 69
    ALN-PDL - Drug Profile 69
    Antibody to Inhibit PD-L1 for Oncology - Drug Profile 70
    Antisense Oligonucleotide to Inhibit PD-L1 for Oncology - Drug Profile 71
    atezolizumab - Drug Profile 72
    avelumab - Drug Profile 86
    AZD-1775 + durvalumab - Drug Profile 92
    Biologic to Inhibit PD-L1 for Immunology - Drug Profile 93
    BMS-936559 - Drug Profile 94
    CA-170 - Drug Profile 96
    CA-327 - Drug Profile 98
    CBA-0710 - Drug Profile 99
    CBT-502 - Drug Profile 100
    Cellular Immunotherapy to Inhibit PD-L1 for Oncology - Drug Profile 101
    CX-072 - Drug Profile 102
    dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 103
    durvalumab - Drug Profile 104
    durvalumab + gefitinib - Drug Profile 115
    durvalumab + IMCgp-100 + tremelimumab - Drug Profile 116
    durvalumab + MEDI-0562 - Drug Profile 117
    durvalumab + MEDI-0680 - Drug Profile 118
    durvalumab + monalizumab - Drug Profile 119
    durvalumab + oleclumab - Drug Profile 120
    durvalumab + selumetinib sulfate - Drug Profile 121
    durvalumab + tremelimumab - Drug Profile 122
    FAZ-053 - Drug Profile 126
    GNS-1480 - Drug Profile 127
    HLX-10 - Drug Profile 128
    HLX-20 - Drug Profile 129
    HTI-1316 - Drug Profile 130
    IO-103 - Drug Profile 131
    KD-033 - Drug Profile 132
    KN-035 - Drug Profile 133
    KY-1003 - Drug Profile 134
    LY-3300054 - Drug Profile 135
    MCLA-145 - Drug Profile 136
    Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 137
    Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 138
    Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 139
    Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 140
    Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 141
    Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile 142
    Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 143
    Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 144
    Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 145
    Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 146
    Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile 147
    Monoclonal Antibody to Inhibit PDL1 for Oncology - Drug Profile 148
    Monoclonal Antibody to Target EGFR and to Inhibit PD-L1 for Oncology - Drug Profile 149
    Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile 150
    Recombinant Proteins to Inhibit PD-L1 for Solid Tumor - Drug Profile 151
    Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile 152
    SNPDL-01 - Drug Profile 153
    STIA-1011 - Drug Profile 154
    STIA-1012 - Drug Profile 155
    STIA-1014 - Drug Profile 156
    STIA-1015 - Drug Profile 157
    Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile 158
    Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 159
    Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 160
    Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 161
    WBP-3155 - Drug Profile 162
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Dormant Projects 163
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Discontinued Products 164
    Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Featured News & Press Releases 165
    Appendix 181
    Methodology 181
    Coverage 181
    Secondary Research 181
    Primary Research 181
    Expert Panel Validation 181
    Contact Us 181
    Disclaimer 182

    List of Tables

    Number of Products under Development for, H2 2016 14
    Number of Products under Development by Therapy Area, H2 2016 15
    Number of Products under Development by Indication, H2 2016 16
    Comparative Analysis by Late Stage Development, H2 2016 19
    Comparative Analysis by Early Stage Products, H2 2016 20
    Number of Products under Development by Companies, H2 2016 21
    Number of Products under Development by Companies, H2 2016 (Contd..1) 22
    Products under Development by Companies, H2 2016 23
    Products under Development by Companies, H2 2016 (Contd..1) 24
    Products under Development by Companies, H2 2016 (Contd..2) 25
    Products under Development by Companies, H2 2016 (Contd..3) 26
    Products under Development by Companies, H2 2016 (Contd..4) 27
    Products under Development by Companies, H2 2016 (Contd..5) 28
    Products under Development by Companies, H2 2016 (Contd..6) 29
    Products under Development by Companies, H2 2016 (Contd..7) 30
    Products under Development by Companies, H2 2016 (Contd..8) 31
    Products under Development by Companies, H2 2016 (Contd..9) 32
    Products under Development by Companies, H2 2016 (Contd..10) 33
    Number of Products under Investigation by Universities/Institutes, H2 2016 34
    Products under Investigation by Universities/Institutes, H2 2016 35
    Assessment by Monotherapy/Combination Products, H2 2016 36
    Number of Products by Stage and Mechanism of Action, H2 2016 37
    Number of Products by Stage and Route of Administration, H2 2016 39
    Number of Products by Stage and Molecule Type, H2 2016 41
    Pipeline by Abeome Corporation, H2 2016 42
    Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 43
    Pipeline by AlphaMab Co., Ltd, H2 2016 44
    Pipeline by AstraZeneca Plc, H2 2016 45
    Pipeline by Aurigene Discovery Technologies Limited, H2 2016 46
    Pipeline by Avacta Group Plc, H2 2016 47
    Pipeline by BeiGene, Ltd., H2 2016 48
    Pipeline by Bristol-Myers Squibb Company, H2 2016 49
    Pipeline by CBT Pharmaceuticals Inc, H2 2016 50
    Pipeline by CytomX Therapeutics, Inc., H2 2016 51
    Pipeline by Eli Lilly and Company, H2 2016 52
    Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53
    Pipeline by Genosco, H2 2016 55
    Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016 56
    Pipeline by Immunocore Limited, H2 2016 57
    Pipeline by IO Biotech ApS, H2 2016 58
    Pipeline by Kadmon Corporation, LLC, H2 2016 59
    Pipeline by Kymab Limited, H2 2016 60
    Pipeline by MedImmune, LLC, H2 2016 61
    Pipeline by Merck KGaA, H2 2016 63
    Pipeline by Merus NV, H2 2016 64
    Pipeline by Novartis AG, H2 2016 65
    Pipeline by PsiOxus Therapeutics Limited, H2 2016 66
    Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 67
    Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 68
    Pipeline by Sorrento Therapeutics, Inc., H2 2016 69
    Pipeline by Sutro Biopharma, Inc., H2 2016 70
    Pipeline by Theravectys SA, H2 2016 71
    Pipeline by Tikcro Technologies, Ltd., H2 2016 72
    Dormant Projects, H2 2016 167
    Discontinued Products, H2 2016 168

    List of Figures

    Number of Products under Development for, H2 2016 14
    Number of Products under Development by Therapy Area, H2 2016 15
    Number of Products under Development by Top 10 Indication, H2 2016 16
    Comparative Analysis by Late Stage Development, H2 2016 19
    Comparative Analysis by Early Stage Products, H2 2016 20
    Assessment by Monotherapy/Combination Products, H2 2016 36
    Number of Products by Stage and Mechanism of Actions, H2 2016 37
    Number of Products by Routes of Administration, H2 2016 38
    Number of Products by Stage and Routes of Administration, H2 2016 38
    Number of Products by Molecule Types, H2 2016 40
    Number of Products by Stage and Molecule Type, H2 2016 40
    Abeome Corporation
    Alnylam Pharmaceuticals, Inc.
    AlphaMab Co., Ltd
    AstraZeneca Plc
    Aurigene Discovery Technologies Limited
    Avacta Group Plc
    BeiGene, Ltd.
    Bristol-Myers Squibb Company
    CBT Pharmaceuticals Inc
    CytomX Therapeutics, Inc.
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd.
    Genosco
    ImmunoCellular Therapeutics, Ltd.
    Immunocore Limited
    IO Biotech ApS
    Kadmon Corporation, LLC
    Kymab Limited
    MedImmune, LLC
    Merck KGaA
    Merus NV
    Novartis AG
    PsiOxus Therapeutics Limited
    Regeneron Pharmaceuticals Inc
    Shanghai Henlius Biotech Co., Ltd.
    Sorrento Therapeutics, Inc.
    Sutro Biopharma, Inc.
    Theravectys SA
    Tikcro Technologies, Ltd.

    Request for Sample

    Report Url https://www.reportsweb.com//programmed-cell-death-1-ligand-1-pd-l1-or-b7-homolog-1-or-cd274-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//programmed-cell-death-1-ligand-1-pd-l1-or-b7-homolog-1-or-cd274-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//programmed-cell-death-1-ligand-1-pd-l1-or-b7-homolog-1-or-cd274-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments